A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease-Reference-Cited by-同舟云学术

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease

Published:2016-10-18 Issue:4 Volume:54 Page:1509-1519
ISSN:1387-2877
Container-title:Journal of Alzheimer's Disease
language:
Short-container-title:JAD

Author:

Brody Mark¹,Liu Enchi²,Di Jianing²,Lu Ming³,Margolin Richard A.⁴,Werth John L.⁵,Booth Kevin⁵,Shadman Anna⁶,Brashear H. Robert⁶,Novak Gerald⁷

Affiliation:

1. Brain Matters Research, Delray Beach, FL, USA

2. Janssen Research & Development, San Diego, CA, USA

3. Janssen Research & Development, Spring House, PA, USA

4. Janssen Alzheimer Immunotherapy, South San Francisco, CA, USA

5. Pfizer Inc., Collegeville, PA, USA

6. Janssen Research & Development, Fremont, CA, USA

7. Janssen Pharmaceutical Research and Development, Titusville, NJ, USA

Publisher

IOS Press

Subject

Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience

Reference12 articles.

1. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease;Bard;Nat Med,2000

2. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study;Rinne;Lancet Neurol,2010

3. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease;Salloway;N Engl J Med,2014

4. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease;Blennow;Arch Neurol,2012

5. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease;McKhann;Neurology,1984

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis;CNS Drugs;2024-03

2. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis;The Annals of Family Medicine;2024-01

3. N-terminal-targeted anti-amyloid monoclonal antibodies illuminate the therapy for Alzheimer’s disease: a systematic review and comprehensive meta-analysis;2023-11-22

4. Passive Immunotherapies Targeting Amyloid-βin Alzheimer’s Disease: A Quantitative Systems Pharmacology Perspective;Molecular Pharmacology;2023-10-31

5. Effects of three kinds of anti-amyloid-β drugs on clinical, biomarker, neuroimaging outcomes and safety indexes: A systematic review and meta-analysis of phase II/III clinical trials in Alzheimer’s disease;Ageing Research Reviews;2023-07